The effect of N-acetylcysteine on plasma total homocysteine levels in hemodialysis

A randomized, controlled study

Allon Friedman, Andrew G. Bostom, Priscilla Laliberty, Jacob Selhub, Douglas Shemin

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

Background: The chronic hemodialysis population has an accelerated rate of cardiovascular morbidity and death. Furthermore, elevated levels of the putative atherothrombotic risk factor homocysteine are almost ubiquitous in this population. Attempts to normalize elevated plasma total homocysteine (tHcy) levels in dialysis patients using pharmacological-dose vitamin therapy or other strategies generally have been unsuccessful. Preliminary uncontrolled evidence suggests that N-acetylcysteine (NAC) may be an effective tHcy-lowering agent. We designed a randomized placebo-controlled study to determine the effect of prolonged oral NAC therapy on lowering tHcy levels in vitamin-replete chronic hemodialysis patients. Methods: Thirty-eight subjects were treated before intervention with a standard dialysis vitamin supplement to ensure a uniform vitamin-replete state. They were then block randomized to treatment with NAC, 1.2 g twice a day, for 4 weeks or matched placebo. Results: There were no significant baseline differences between the two groups, although differences in pyridoxal 5′-phosphate (active form of vitamin B6) levels approached significance (P = 0.06). In a paired analysis, there was no statistically significant difference between the NAC and placebo groups. NAC was very well tolerated in hemodialysis patients. Conclusion: This randomized placebo-controlled trial found that chronic oral NAC therapy did not significantly reduce tHcy levels in hemodialysis patients. Although a larger sample size theoretically could have increased the statistical significance between groups, implications of the potentially very modest reduction in tHcy levels are not yet known. Finally, based on this limited study, NAC appears to be a safe and well-tolerated therapy in the hemodialysis population.

Original languageEnglish
Pages (from-to)442-446
Number of pages5
JournalAmerican Journal of Kidney Diseases
Volume41
Issue number2
DOIs
StatePublished - Feb 1 2003

Fingerprint

Acetylcysteine
Homocysteine
Renal Dialysis
Vitamins
Placebos
Dialysis
Population
Therapeutics
Vitamin B 6
Pyridoxal Phosphate
Sample Size
Randomized Controlled Trials
Pharmacology
Morbidity

Keywords

  • Cardiovascular
  • Dialysis
  • Homocysteine
  • N-Acetylcysteine (NAC)

ASJC Scopus subject areas

  • Nephrology

Cite this

The effect of N-acetylcysteine on plasma total homocysteine levels in hemodialysis : A randomized, controlled study. / Friedman, Allon; Bostom, Andrew G.; Laliberty, Priscilla; Selhub, Jacob; Shemin, Douglas.

In: American Journal of Kidney Diseases, Vol. 41, No. 2, 01.02.2003, p. 442-446.

Research output: Contribution to journalArticle

Friedman, Allon ; Bostom, Andrew G. ; Laliberty, Priscilla ; Selhub, Jacob ; Shemin, Douglas. / The effect of N-acetylcysteine on plasma total homocysteine levels in hemodialysis : A randomized, controlled study. In: American Journal of Kidney Diseases. 2003 ; Vol. 41, No. 2. pp. 442-446.
@article{87e26cc542e343b0bc3d8f92fe4b336d,
title = "The effect of N-acetylcysteine on plasma total homocysteine levels in hemodialysis: A randomized, controlled study",
abstract = "Background: The chronic hemodialysis population has an accelerated rate of cardiovascular morbidity and death. Furthermore, elevated levels of the putative atherothrombotic risk factor homocysteine are almost ubiquitous in this population. Attempts to normalize elevated plasma total homocysteine (tHcy) levels in dialysis patients using pharmacological-dose vitamin therapy or other strategies generally have been unsuccessful. Preliminary uncontrolled evidence suggests that N-acetylcysteine (NAC) may be an effective tHcy-lowering agent. We designed a randomized placebo-controlled study to determine the effect of prolonged oral NAC therapy on lowering tHcy levels in vitamin-replete chronic hemodialysis patients. Methods: Thirty-eight subjects were treated before intervention with a standard dialysis vitamin supplement to ensure a uniform vitamin-replete state. They were then block randomized to treatment with NAC, 1.2 g twice a day, for 4 weeks or matched placebo. Results: There were no significant baseline differences between the two groups, although differences in pyridoxal 5′-phosphate (active form of vitamin B6) levels approached significance (P = 0.06). In a paired analysis, there was no statistically significant difference between the NAC and placebo groups. NAC was very well tolerated in hemodialysis patients. Conclusion: This randomized placebo-controlled trial found that chronic oral NAC therapy did not significantly reduce tHcy levels in hemodialysis patients. Although a larger sample size theoretically could have increased the statistical significance between groups, implications of the potentially very modest reduction in tHcy levels are not yet known. Finally, based on this limited study, NAC appears to be a safe and well-tolerated therapy in the hemodialysis population.",
keywords = "Cardiovascular, Dialysis, Homocysteine, N-Acetylcysteine (NAC)",
author = "Allon Friedman and Bostom, {Andrew G.} and Priscilla Laliberty and Jacob Selhub and Douglas Shemin",
year = "2003",
month = "2",
day = "1",
doi = "10.1053/ajkd.2003.50054",
language = "English",
volume = "41",
pages = "442--446",
journal = "American Journal of Kidney Diseases",
issn = "0272-6386",
publisher = "W.B. Saunders Ltd",
number = "2",

}

TY - JOUR

T1 - The effect of N-acetylcysteine on plasma total homocysteine levels in hemodialysis

T2 - A randomized, controlled study

AU - Friedman, Allon

AU - Bostom, Andrew G.

AU - Laliberty, Priscilla

AU - Selhub, Jacob

AU - Shemin, Douglas

PY - 2003/2/1

Y1 - 2003/2/1

N2 - Background: The chronic hemodialysis population has an accelerated rate of cardiovascular morbidity and death. Furthermore, elevated levels of the putative atherothrombotic risk factor homocysteine are almost ubiquitous in this population. Attempts to normalize elevated plasma total homocysteine (tHcy) levels in dialysis patients using pharmacological-dose vitamin therapy or other strategies generally have been unsuccessful. Preliminary uncontrolled evidence suggests that N-acetylcysteine (NAC) may be an effective tHcy-lowering agent. We designed a randomized placebo-controlled study to determine the effect of prolonged oral NAC therapy on lowering tHcy levels in vitamin-replete chronic hemodialysis patients. Methods: Thirty-eight subjects were treated before intervention with a standard dialysis vitamin supplement to ensure a uniform vitamin-replete state. They were then block randomized to treatment with NAC, 1.2 g twice a day, for 4 weeks or matched placebo. Results: There were no significant baseline differences between the two groups, although differences in pyridoxal 5′-phosphate (active form of vitamin B6) levels approached significance (P = 0.06). In a paired analysis, there was no statistically significant difference between the NAC and placebo groups. NAC was very well tolerated in hemodialysis patients. Conclusion: This randomized placebo-controlled trial found that chronic oral NAC therapy did not significantly reduce tHcy levels in hemodialysis patients. Although a larger sample size theoretically could have increased the statistical significance between groups, implications of the potentially very modest reduction in tHcy levels are not yet known. Finally, based on this limited study, NAC appears to be a safe and well-tolerated therapy in the hemodialysis population.

AB - Background: The chronic hemodialysis population has an accelerated rate of cardiovascular morbidity and death. Furthermore, elevated levels of the putative atherothrombotic risk factor homocysteine are almost ubiquitous in this population. Attempts to normalize elevated plasma total homocysteine (tHcy) levels in dialysis patients using pharmacological-dose vitamin therapy or other strategies generally have been unsuccessful. Preliminary uncontrolled evidence suggests that N-acetylcysteine (NAC) may be an effective tHcy-lowering agent. We designed a randomized placebo-controlled study to determine the effect of prolonged oral NAC therapy on lowering tHcy levels in vitamin-replete chronic hemodialysis patients. Methods: Thirty-eight subjects were treated before intervention with a standard dialysis vitamin supplement to ensure a uniform vitamin-replete state. They were then block randomized to treatment with NAC, 1.2 g twice a day, for 4 weeks or matched placebo. Results: There were no significant baseline differences between the two groups, although differences in pyridoxal 5′-phosphate (active form of vitamin B6) levels approached significance (P = 0.06). In a paired analysis, there was no statistically significant difference between the NAC and placebo groups. NAC was very well tolerated in hemodialysis patients. Conclusion: This randomized placebo-controlled trial found that chronic oral NAC therapy did not significantly reduce tHcy levels in hemodialysis patients. Although a larger sample size theoretically could have increased the statistical significance between groups, implications of the potentially very modest reduction in tHcy levels are not yet known. Finally, based on this limited study, NAC appears to be a safe and well-tolerated therapy in the hemodialysis population.

KW - Cardiovascular

KW - Dialysis

KW - Homocysteine

KW - N-Acetylcysteine (NAC)

UR - http://www.scopus.com/inward/record.url?scp=0037308180&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037308180&partnerID=8YFLogxK

U2 - 10.1053/ajkd.2003.50054

DO - 10.1053/ajkd.2003.50054

M3 - Article

VL - 41

SP - 442

EP - 446

JO - American Journal of Kidney Diseases

JF - American Journal of Kidney Diseases

SN - 0272-6386

IS - 2

ER -